Solventum (NYSE:SOLV – Get Free Report) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 6.500-6.650 for the period, compared to the consensus estimate of 6.380. The company issued revenue guidance of -. Solventum also updated its FY24 guidance to $6.50-6.65 EPS.
Analyst Ratings Changes
Several brokerages recently issued reports on SOLV. The Goldman Sachs Group lifted their price target on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a report on Monday, August 12th. BTIG Research started coverage on shares of Solventum in a report on Thursday, September 5th. They set a “neutral” rating on the stock. Morgan Stanley cut their target price on shares of Solventum from $70.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th. Wolfe Research started coverage on shares of Solventum in a research report on Thursday, September 26th. They set a “peer perform” rating on the stock. Finally, Stifel Nicolaus started coverage on shares of Solventum in a research report on Tuesday, October 8th. They set a “buy” rating and a $82.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $65.00.
Get Our Latest Research Report on SOLV
Solventum Trading Down 3.5 %
Solventum (NYSE:SOLV – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.10. The firm had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.05 billion. The business’s quarterly revenue was up .2% on a year-over-year basis. Analysts forecast that Solventum will post 6.59 earnings per share for the current year.
Solventum Company Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Featured Articles
- Five stocks we like better than Solventum
- Technology Stocks Explained: Here’s What to Know About Tech
- California Resources Stock Could Be a Huge Long-Term Winner
- How to Use Stock Screeners to Find Stocks
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.